On November 19, the GD2-CART cell therapy clinical research on childhood neuroblastoma was held at the Children’s Hospital of Nanjing Medical University (Nanjing Children’s Hospital). The convening of this conference marked the GD2-CART cell therapy for childhood neuroblastoma. The tumor project clinical research started.
The development and challenges of "off-the-shelf" allogeneic CAR-T cells Nanjing Cati Medicine July 10 1. Autologous CAR-T cell therapy and allogeneic CAR-T cell therapy 2. Allogeneic CAR-T cell therapy The advantages.Source: From healthy donors, these cells are not affected by the immune effect of cancer, nor are they affected by chemotherapeutic drugs, which are different from the formation of the patient's autologous T cells. Cycle: Compared with autologous CAR-T treatment, allogeneic CAR-T can shorten the treatment cycle and can be prepared in batches
At present, CAR-T cell immunotherapy, as an emerging immunotherapy in recent years, has achieved significant effects in hematological tumors, but the toxic side effects have largely limited the wide application of CAR-T cells, especially cytokine release synthesis. Sign (CRS).
Katy Medical and Shenghe Pharmaceuticals signed a strategic cooperation agreement Nanjing Katy Medical April 16, 2020, April 15, 2020, Nanjing Katy Medical Technology Co., Ltd. (hereinafter referred to as Katy Medical) and Nanjing Shenghe Pharmaceutical Co., Ltd. (Hereinafter referred to as Shenghe Pharmaceutical) signed a strategic cooperation agreement in the Medical Valley of Jiangbei New Area, Nanjing. Chairman Wang Enxiu of Kati Medicine, Deputy General Manager of Shenghe Pharmaceutical and Dean of Research Institute Zhao Liwen signed a strategic cooperation agreement on behalf of both companies, and Luo Shuqin, Deputy Director of Life and Health Office of Jiangbei New District, Nanjing witnessed the signing.
Congratulations on the successful conclusion of the 2020 BPIT Biopharmaceutical Innovation Technology Conference. Winning in Nanjing·The Future of Science and Technology Salutes the "Golden Decade" and witnesses the new goals and new milestones of China's innovative drugs! From July 20th to 21st, the 2020 BPIT Biopharmaceutical Innovation Technology Conference hosted by Nanjing Jiangbei New Area was grandly held. The guests gathered at the conference. Dr. Wang Enxiu, Chairman & CEO of our company, was invited to present a gluttonous feast in the field of biopharmaceuticals with academician Chen Kaixian and other leading domestic bio-innovative drugs and industry elites in the pharmaceutical field.